Albireo is the leader in bile acid science and is leveraging its expertise in bile acid modulation to bring novel, potentially transformative medicines to patients.
Based on mechanism of action and over a decade of gold standard R&D, we believe bile acid modulation with IBAT inhibition and other novel mechnanisms may benefit people with a wide range of cholestatic liver diseases.
Albireo is the leader in bile acid science and is leveraging its expertise in bile acid modulation to bring novel, potentially transformative medicines to patients.
Based on mechanism of action and over a decade of gold standard R&D, we believe bile acid modulation with IBAT inhibition and other novel mechnanisms may benefit people with a wide range of cholestatic liver diseases.
We are relentlessly focused on bringing new medicines to patients.
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate.
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit nunc cursus velit elit. Sed dictum lacus consequat vitae. sed dictum lacus consequat vitae ipsum dolor sit amet.
Lorem ipsum dolor sit amet, consectetur adipiscing elit nunc cursus velit elit. Sed dictum lacus consequat vitae. sed dictum lacus consequat vitae ipsum dolor sit amet.
If you are an exceptional teammate driven by a commitment to helping patients, Albireo is the right place for you.
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Bylvay is the first drug approved for the treatment of pruritus in patients with progressive familial intrahepatic cholestasis (PFIC), a spectrum of life-threatening, rare, pediatric liver diseases.
Odevixibat is a potent, non-systemic ileal bile acid transport inhibitor (IBATi). Albireo is developing odevixibat to treat rare pediatric cholestatic liver diseases.
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Announcements, news and more
Learn MoreLearn more about Albireo
Learn MoreLorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate.
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate.